[Efficacy of TAS-102]

Area of Science:

• Oncology
• Pharmacology
• Gastroenterology

Background:

• Metastatic colorectal cancer (mCRC) treatment faces challenges with drug approval delays, known as "druglag."
• Trifluridine/tipiracil (TAS-102) development for mCRC has navigated unique regulatory pathways.
• Previous clinical trials indicated potential efficacy for TAS-102 in advanced cancers.

Purpose of the Study:

• To present comprehensive data on the efficacy and safety of TAS-102 in metastatic colorectal cancer.
• To analyze results from Japanese Phase I/II trials and the global Phase III RECOURSE trial.
• To provide insights into the clinical performance of TAS-102, addressing the "druglag" phenomenon.

Main Methods:

• Review of data from Phase I/II clinical trials conducted in Japan.
• Analysis of results from the global Phase III RECOURSE trial.
• Evaluation of efficacy endpoints and safety profiles (side effects) from all included trials.

Main Results:

• The Japanese Phase II trial demonstrated positive results, leading to early approval in Japan.
• The global Phase III RECOURSE trial confirmed the efficacy of TAS-102 in a broader patient population.
• Detailed efficacy and side effect data from these trials are presented.

Conclusions:

• TAS-102 has proven effective in treating metastatic colorectal cancer.
• The drug's approval pathway highlights a successful navigation of regulatory processes, potentially mitigating "druglag."
• Further understanding of TAS-102's efficacy and safety profile is crucial for clinical application.